warfarin "orion" 2,5 mg tabletter
orion corporation - warfarinnatrium - tabletter - 2,5 mg
piperacillin/tazobactam "fresenius kabi" 2+0,25 g pulver til infusionsvæske, opløsning
fresenius kabi ab - piperacillinnatrium, tazobactamnatrium - pulver til infusionsvæske, opløsning - 2+0,25 g
piperacillin/tazobactam "reig jofre" 2+0,25 g pulver til infusionsvæske, opløsning
laboratorio reig jofre s.a. - piperacillin, tazobactam - pulver til infusionsvæske, opløsning - 2+0,25 g
piperacillin/tazobactam "stragen" 2 g+0,25 g pulver til infusionsvæske, opløsning
stragen nordic a/s - piperacillinnatrium, tazobactamnatrium - pulver til infusionsvæske, opløsning - 2 g+0,25 g
piptazira 2 g+0,25 g pulver til infusionsvæske, opløsning
pfizer aps - piperacillinnatrium, tazobactamnatrium - pulver til infusionsvæske, opløsning - 2 g+0,25 g
maviret
abbvie deutschland gmbh co. kg - glecaprevir, pibrentasvir - hepatitis c kronisk - antivirale midler til systemisk anvendelse - maviret is indicated for the treatment of chronic hepatitis c virus (hcv) infection in adults and children aged 3 years and older. maviret coated granules is indicated for the treatment of chronic hepatitis c virus (hcv) infection in children 3 years and older.
marevan 2,5 mg tabletter
orifarm healthcare a/s - warfarinnatrium - tabletter - 2,5 mg
warfarinnatrium "2care4" 2,5 mg tabletter
2care4 aps - warfarinnatrium - tabletter - 2,5 mg
adempas
bayer ag - riociguat - hypertension, lunge - antihypertensive midler til pulmonal arteriel hypertension - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. effekten har været vist i en pah befolkningen, herunder aetiologies af idiopatisk eller arvelige pah eller pah, der er forbundet med bindevævssygdom. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.
alli (previously orlistat gsk)
glaxosmithkline (ireland) limited - orlistat - fedme - antiobesity preparations, excl. diætprodukter - alli er indiceret til vægttab hos voksne, der er overvægtige (kropsmasseindeks, bmi, ≥ 28 kg / m2) og bør tages sammen med en mildt hypokalorisk, fedtfattig kost.